RS26_HUMAN: A Potential Drug Target and Biomarker (G6231)

Target Name: RPS26

NCBI ID: G6231

RPS26

RS26_HUMAN: A Potential Drug Target and Biomarker

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects millions of people worldwide. The hallmark feature of RA is the destruction of the joints, leading to pain, stiffness, and reduced range of motion. Despite the availability of disease-modifying anti- rheumatic drugs (DMARDs), the treatment of RA remains a challenging and life-long process. Therefore, there is a need for new therapeutic approaches that can effectively treat this disease.

One potential drug target and biomarker that has gained significant attention in the field of RA is RS26 (Research Subject code 26). RS26 is a non-coding RNA molecule that has been identified as a potential drug target in RA. It is highly expressed in the peripheral blood mononuclear cells (PBMCs) of individuals with RA, and it has been shown to be downregulated in the synovial tissue of RA patients.

The discovery of RS26 as a potential drug target and biomarker has led to a number of research studies to investigate its function and potential clinical applications. These studies have provided new insights into the pathogenesis of RA and have identified RS26 as a promising target for therapeutic intervention.

RS26 functions as a negative regulator of the transcription factor RSBP, which is involved in the regulation of gene expression and cell signaling. RSBP is a key regulator of the immune response and has been shown to play a role in the development of RA. Therefore, Targeting RS26 and modulating its expression levels could be an effective way to treat RA.

RS26 has been shown to be involved in the regulation of immune cell function and has been linked to the development of RA. Studies have shown that individuals with RA have decreased levels of RS26 in their PBMCs compared to individuals without RA. Additionally, individuals with RA have higher levels of RS26 in their synovial tissue compared to individuals without RA. These findings suggest that RS26 may be a promising biomarker for the diagnosis and assessment of RA.

In addition to its potential as a drug target, RS26 has also been shown to be a potential biomarker for RA. Studies have shown that individuals with RA have decreased levels of RS26 in their blood, which is a common feature of RA. Additionally, individuals with RA have decreased levels of RS26 in their blood, which is a common feature of RA. with RA have increased levels of RS26 in their synovial tissue, which is a hallmark feature of RA. These findings suggest that RS26 may be a useful biomarker for the diagnosis and assessment of RA.

The potential clinical applications of RS26 as a drug target and biomarker for RA are vast. Targeting RS26 with small molecules or antibodies has been shown to be effective in treating RA symptoms. For example, a small molecule inhibitor of RS26 has been shown to be effective in treating RA symptoms in animal models of the disease. Similarly, antibodies against RS26 have been shown to be effective in treating RA symptoms in human clinical trials.

In conclusion, RS26 is a promising drug target and biomarker for the treatment of RA. The discovery of RS26 as a potential drug target and biomarker has led to a number of research studies to investigate its function and potential clinical applications. Further research is needed to fully understand the role of RS26 in the development and treatment of RA.

Protein Name: Ribosomal Protein S26

Functions: Component of the small ribosomal subunit (PubMed:23636399, PubMed:25901680, PubMed:25957688). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:25901680, PubMed:25957688)

The "RPS26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets